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Review Article
It is estimated that more than 36 million people worldwide 
are living with HIV/AIDS.1 Over the past 20 years, man-
agement of HIV with antiretroviral therapy (ART) has led 
to substantial improvements in morbidity and mortality. 
Individuals who initiated ART in the past 10 years and 
achieved adequate CD4 counts have life expectancy close 
to that of the general population.2 The success of ART has 
changed the outlook of HIV from a short life span to a man-
ageable chronic disease. As the population of people living 
with HIV (PLWH) age, their health care needs become 
more complex as age-related comorbidities develop.
In the pre-ART era, malignancies in PLWH were consid-
ered to be AIDS-defining malignancies (ADMs), with 
Kaposi sarcoma and non-Hodgkin lymphoma (NHL) 
accounting for 99% of ADMs.3 In the current ART era, the 
decrease in mortality rates has led to a significant decline of 
ADMs but increased incidence of non–AIDS-defining 
malignancies (NADMs), with PLWH having a higher risk of 
NADMs than the general population.4-8 The most frequent 
NADMs in PLWH include lung, anal, prostate, liver, breast, 
head/neck, rectal, and renal cancers.4,5,9,10 Contributors to 
development of NADMs include aging, presence of viral 
coinfections, or cigarette smoking. A recent modeling study 
projected a shift in the cancer burden among PLWH, 
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Abstract
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by 
both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of 
combination therapies. Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and 
EMBASE to identify studies of malignancies in PLWH in the modern era. Study Selection and Data Extraction: Article 
bibliographies and drug interaction databases were reviewed. Search terms included HIV, antiretroviral therapy, antineoplastic 
agents, malignancies, and drug interactions. Data Synthesis: In the pre–antiretroviral therapy (ART) era, malignancies in 
PLWH were AIDS-defining illnesses, and life expectancy was shorter. Nowadays, PLWH are living longer and developing 
malignancies, including lung, anal, and prostate cancers. Concurrently, the oncology landscape has evolved, with novel 
oral targeted agents and immunotherapies becoming routine elements of care. The increased need for and complexity 
with antineoplastics in PLWH has led to recommendations for multidisciplinary care of this unique population. Evaluation 
of DDIs requires review of metabolic pathways, absorption mechanisms, and various drug transporters associated with 
antineoplastics and ART. Relevance to Patient Care and Clinical Practice: This review summarizes available data 
of non–AIDS-defining malignancies, principles of HIV care in the patient with malignancy, and guidance for assessing 
DDIs between antineoplastics and ART. Summary DDI tables provide point-of-care recommendations. Conclusions: 
The availability of ART has transformed AIDS into a chronic medical condition, and PLWH are experiencing age-related 
malignancies. Pharmacists play an important role in the management of this patient population.
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suggesting that by 2030 prostate and lung cancers will 
emerge as the most common NADMs.4 These epidemiologi-
cal shifts in the observed types of cancers and the aging of 
the PLWH population increase the likelihood that PLWH 
will receive concomitant antineoplastics and ART.
Traditionally, management of malignancies has involved 
the administration of intravenous cytotoxic agents given 
over multiple cycles with defined time periods. In the past 
decade, the oncology landscape has dramatically changed, 
with exponential growth of numbers of novel oral targeted 
agents and immunotherapies. In the past 5 years, more than 
60 new active substances have been launched for 23 differ-
ent tumor types and many more immunotherapies, and tar-
geted agents are still in the pipeline.11 As malignancy 
treatment strategies become more complex, multiple lines 
of therapy are used, and individual agents may be adminis-
tered for longer periods of time than previously. Although 
oral antineoplastics have been advantageous for patients 
with convenience and improved quality of life, there are 
additional considerations for patient safety, such as drug 
interactions, comorbidities, and reduced contact with the 
health care system. Patients with malignancies receive mul-
tiple medications both for cancer management and for sup-
portive care needs.
The increased need for antineoplastics in PLWH and the 
additional complexities associated with the modern cancer 
chemotherapies has led to recommendations for multidisci-
plinary care of this unique population.10,12 It is recom-
mended that PLWH who develop cancer should receive 
treatment for both conditions as recommended by standard 
guidelines for either condition, with drug adjustments as 
necessary.10 Information regarding PLWH with concomi-
tant malignancies, particularly management of drug interac-
tions, is scarce. This review summarizes available data of 
managing selected NADMs in PLWH and HIV in individu-
als affected by both conditions.
Data Sources
Literature searches were performed in PubMed and 
EMBASE (2005 to December 2018) to identify studies of 
malignances in PLWH in the modern ART era. Article bib-
liographies and drug interaction databases were reviewed. 
Search terms included HIV, antiretroviral therapy, antineo-
plastic agents, malignancies, drug interactions, acquired 
immunodeficiency syndrome, immunotherapy, drug ther-
apy/combination, HIV infections/drug therapy, and neo-
plasms/drug therapy. Animal and non-English language 
studies were excluded. Information from Food and Drug 
Administration (FDA)-approved drug products, the FDA 
Drug Development and Drug Interactions website, and clin-
ical practice guidelines were the main sources utilized to 
assess metabolic pathways of medications.13-15 To predict 
potential drug-drug interactions (DDIs), prescribing infor-
mation and the University of Liverpool HIV drug-drug 
interaction checker were consulted for each drug.13,16 
Attention was given to prior DDI studies, case reports/case 
series, in vitro data, and modeling studies.
Non–AIDS-Defining Malignancies
Lung Cancer
The risk of lung cancer is generally 2 to 3 times higher in 
PLWH compared with the HIV-negative population.9,17,18 
Furthermore, PLWH diagnosed with lung cancer have a 
higher risk for mortality. A meta-analysis of 12 observa-
tional studies that evaluated the impact of HIV infection on 
the risk of mortality among lung cancer patients reported a 
pooled relative risk of mortality risk among lung cancer 
patients with HIV infection of 1.48 (95% CI = 1.22-1.78).19 
The mechanisms underlying the increased rates of lung can-
cer are multifactorial. Cigarette smoke, along with HIV 
infection and chronic inflammation, exacerbates oxidative 
stress, leading to oxidative DNA lesions and DNA double-
strand breaks.20 PLWH are also more likely to be diagnosed 
with lung cancer at a younger age compared with the gen-
eral population. It is hypothesized that these patients could 
be predisposed to other immunological risk factors that are 
associated with the development of lung cancer.20
Some recommend that PLWH and non–small-cell lung 
cancer (NSCLC) should be treated as per usual manage-
ment of NSCLC.10 Evidence or guidance is not clear for 
other lung cancers. PLWH and NSCLC may be more likely 
to have benign lung nodules; hence, infectious etiologies 
must be excluded. Reasons for poor performance status in 
PLWH should be evaluated when making treatment deci-
sions because treatment of NSCLC may potentially reverse 
cancer-related symptoms.10 Modifications of cancer therapy 
should not be made solely on the basis of HIV status. As 
immunotherapy checkpoint inhibitors such as pembroli-
zumab are becoming more commonly used in NSCLC, this 
raises the question of whether these agents may benefit 
PLWH who are diagnosed with lung cancer. Limited studies 
suggest that tumor PD-L1 expression is similar or higher in 
PLWH.21,22 Two case series were published with combined 
15 patients who received ART and either pembrolizumab or 
nivolumab for NSCLC.23,24 One patient (with baseline CD4 
count of 194 cells/mm3) received 9 doses of nivolumab and 
experienced grade 3 pneumonitis.24 No other grade 3 or 4 
immune-related adverse events were noted. Ongoing stud-
ies are evaluating whether PD-1 inhibitors are safe to be 
administered in PLWH.25
Anal Cancer
Anal cancer is common among PLWH. In the United States, 
the risk of developing anal cancer is 19-fold higher (stan-
dardized incidence ratio [SIR] = 19.1; 95% CI = 
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18.1-20.0) compared with the general population.26 Anal 
cancer, similar to cervical cancer, is caused by persistent 
human papillomavirus (HPV) infection because of immu-
nosuppression; HPV 16 and 18 subtypes are predominantly 
associated with anal cancer. Anal cancer may arise from a 
precursor dysplastic lesion—namely, anal squamous epi-
thelial neoplasia (AIN)—which is more commonly 
observed in PLWH. AIN is a known precursor to anal can-
cer and is highly influenced by HIV seropositivity, low CD4 
counts, and serotype of HPV infection. A recent study found 
no evidence to support an adjunctive role for HPV vaccina-
tion to improve outcomes to prevent new anal HPV infec-
tions or for treatment of anal high-grade squamous 
intraepithelial lesions on biopsy in PLWH who are aged 27 
years or older.27
Treatment of anal cancer in PLWH, which convention-
ally involves chemoradiation, should follow usual manage-
ment standards as for those who are not infected with HIV.10 
Recent studies have evaluated whether cetuximab, an epi-
dermal growth receptor inhibitor, in addition to concurrent 
radiation with cisplatin and 5-fluorouracil would improve 
locoregional control in patients with squamous cell anal 
cancer.28 However, more than 70% of patients receiving this 
regimen experienced grade 3 or higher toxicities, with 26% 
experiencing grade 4 toxicities. Therefore, the addition of 
cetuximab to routine care is not recommended for manage-
ment of anal cancer in PLWH.10 Findings from an observa-
tional study that evaluated the survival and safety outcomes 
in PLWH who have good control of their HIV infections 
suggested that HIV-positive patients with anal cancer had 
survival outcomes similar to anal cancer patients who were 
HIV negative.29 On multivariate analysis, only male gender 
and higher stage of cancer were predictive of worse survival 
outcomes.
Other Cancers
The status of immunosuppression is often linked to 
increased risk of cancer in PLWH. However, several reports 
have suggested that the incidence rates of a number of can-
cers that are commonly screened in the community (such as 
breast cancer, prostate cancer, and colorectal cancer) may 
be much lower in PLWH. The incidence of breast, prostate, 
and colorectal cancer in PLWH against the general popula-
tion were compared using data from the HIV/AIDS Cancer 
Match Study (1996-2012) in the United States.30 It was 
reported that PLWH had lower rates of invasive breast (SIR 
= 0.63; 95% CI = 0.58-0.68), prostate (SIR = 0.48; 95% 
CI = 0.46-0.51), proximal colon (SIR = 0.67; 95% CI = 
0.59-0.75), distal colon (SIR = 0.51; 95% CI = 0.43-0.59), 
and rectal cancers (SIR = 0.69; 95% CI = 0.61-0.77). This 
lower risk is present for both early-stage tumors that are 
primarily detected by screening and larger tumors that are 
likely clinically detected, arguing against a screening effect 
as the primary explanation for these HIV-related cancer 
deficits. Some studies suggest that HIV could potentially 
affect breast and prostate cancer risk by altering hormone 
levels, hence possibly leading to a lower risk of developing 
cancer.31,32 Specific recommendations for management of 
these cancers in PLWH are not available.
Management of HIV Infection in the 
Patient With Cancer
Initiation/Continuation of ART
Initiation of ART in PLWH regardless of CD4 count is rec-
ommended to reduce morbidity and mortality associated 
with the infection and to prevent transmission.15 ART 
should not be delayed by a diagnosis of malignancy; simi-
larly, assessment of HIV infection and subsequent initiation 
of ART should not delay treatment of the malignancy.10,15 A 
consideration for ART initiation in some patients is the risk 
of unmasking lymphoma immune reconstitution inflamma-
tory syndrome (IRIS); this was studied in 482 patients with 
lymphoma in the Center for AIDS Research Network of 
Integrated Clinical Systems.33 A total of 56 (12%) of these 
patients met the criteria for unmasking lymphoma IRIS, and 
this occurred a median of 2.2 months before the diagnosis 
of lymphoma was made. However, the benefits of ART 
treatment on lymphoma mortality are substantial. Another 
assessment of 224 patients diagnosed with lymphoma 
between 1996 and 2011 who were alive 6 months following 
diagnosis and having at least 2 HIV RNA values showed 
that the adjusted hazard ratio for mortality with cumulative 
HIV viremia during the 6 months following diagnosis was 
1.35 (95% CI = 1.11-1.65).34 The authors concluded that 
the occurrence of each 1-unit log
10
 increase in HIV RNA 
throughout the 6 months following lymphoma diagnosis 
results in a 35% increase in mortality, thus emphasizing the 
importance of early initiation of ART.
ART should be initiated immediately, and it is preferable 
to start at least 7 days prior to initiation of cancer treat-
ment.10 If antineoplastics have already been started, ART 
can be initiated once tolerance to the cancer regimen has 
been established. There may be exceptions where ART 
should be initiated immediately without regard for timing 
of antineoplastics, such as in patients with progressive mul-
tifocal leukoencephalopathy.10 Additionally, if a patient is 
coinfected with hepatitis B virus, the ART components 
should provide coverage for both viruses.10,15
Two nucleoside reverse transcriptase inhibitors (NRTIs) 
in combination with a an integrase strand transfer inhibitor 
(INSTI) is a recommended initial regimen.15 INSTI-based 
regimens are preferred because they are effective and are 
better tolerated than protease inhibitor (PI)- or nonnucleo-
side reverse transcriptase inhibitor (NNRTI)-based regi-
mens.15 Studies have demonstrated durable efficacy with 
Olin et al 815
INSTI-based regimens in patients with cancer.35,36 One 
observational cohort study of 30 patients who initiated or 
were changed to a raltegravir-based ART as a result of a 
cancer diagnosis showed a mean increase in CD4 count of 
49 cells/mL; only 1 discontinuation as a result of virological 
failure, which was attributed to nonadherence; and no addi-
tive adverse effects attributed to ART.35 A retrospective 
study in 154 patients that compared various HIV regimens 
showed that INSTI-based treatment was 9 times (95% CI = 
1.4-50.8) more likely to be effective, as shown by HIV 
RNA <200 copies/mL at 6 months, than PI-based treat-
ment.36 Adverse effects related to ART occurred in 35% 
(17/49) of patients receiving PIs and 3% (1/30) of patients 
receiving INSTIs.36 Thus, INSTI-based treatment is an 
attractive option for this population of patients.
Options for INSTI-based regimens include bictegravir/
tenofovir alafenamide (TAF)/emtricitabine, dolutegravir/
abacavir/lamivudine (only if HLA-B*5701 testing is nega-
tive), dolutegravir plus tenofovir/emtricitabine, or raltegra-
vir plus tenofovir/emtricitabine.15 Tenofovir is available as 
either tenofovir disoproxil fumarate (TDF) or TAF; the for-
mer is associated with less elevations in lipids, whereas the 
latter has less renal and bone toxicity. Recommended initial 
regimens for patients in certain clinical situations that may 
warrant use of alternative agents that have less data in clini-
cal trials or may be disadvantageous with respect to other 
characteristics, such as adverse effects or pill burden, are 
also described. These include PI-based and NNRTI-based 
regimens.15 However, because of an increased risk of toxic-
ity and DDIs, use of these regimens requires caution in the 
patient being treated for cancer.
An HIV treatment regimen should be individualized for 
each patient based on virological efficacy, comorbidities, 
DDI potential, adverse effect profile, dosing frequency, 
food requirements, pill burden, results of resistance testing, 
and cost.15 For example, raltegravir-, bictegravir-, and 
dolutegravir-based regimens can be taken without regard to 
food; this may be useful for patients who experience che-
motherapy-induced nausea and vomiting. Additionally, use 
of TAF instead of TDF is preferable in those patients who 
are at risk of or who already have bone mineral density loss 
secondary to antineoplastics. HIV specialists can assist in 
optimal regimen selection for patients with unique needs. 
Communication and coordination between specialists is 
important for timely treatment initiation and follow-up.37
For patients who are already taking ART, interruptions 
should be avoided because this leads to immune system 
compromise, opportunistic infections (OIs), and death.38 In 
fact, continuing ART may lead to improved tolerance of 
cancer chemotherapy, better response rates, and improved 
survival.10 The ART regimen may need to be modified to 
reduce the risk of DDIs and adverse effects, and this should 
be done in collaboration with HIV and oncology pharma-
cists.10 Recognition of factors that may compromise 
virological efficacy in cancer patients is helpful in taking a 
proactive approach to adjustments in ART as needed. For 
example, a patient may have difficulty swallowing tablets 
and capsules as a result of the cancer and/or its chemother-
apy, thus requiring use of liquid or crushable dosage forms.37 
Changes to a patient’s current regimen can be made prior to 
initiation of antineoplastics to minimize toxicity, avoid 
DDIs, and prevent missed doses.37 As with initiation of 
treatment, changes in treatment should be discussed among 
providers to determine the optimal approach for the indi-
vidual patient.
ART and Antineoplastic Drug Interactions
Assessing possible DDIs between antineoplastics and ART 
is a crucial component of care in PLWH and malignancy. 
Metabolic pathways, absorption mechanisms, and the role 
of various drug transporters should be considered when 
coadministering antineoplastics and ART. Information 
regarding metabolic pathways for the most commonly used 
agents in PLWH and selected malignancies is given in 
Tables 1 and 2.13-15 Information about less commonly pre-
scribed ART is not included. If an ART not listed in the 
tables is part of a patient’s regimen, clinicians should con-
sider consulting with an expert in HIV pharmacology to 
discern any potential DDI.
Many ART and antineoplastic drugs are metabolized by 
the hepatic cytochrome P450 (CYP) system and can also 
induce or inhibit the CYP enzymes. Among ART, strong CYP 
inhibitors, such as ritonavir and cobicistat, and strong CYP 
inducers, including efavirenz, have a high probability of 
interactions with antineoplastics metabolized by the CYP.14,15 
The uridine diphosphate glucuronosyltransferase (UGT) 1A1 
enzyme is responsible for the glucuronidation of INSTIs and 
several antineoplastic drugs, including etoposide, irinotecan, 
axitinib, and belinostat. The PI, atazanavir, and several tyro-
sine kinase inhibitors have the potential to inhibit UGT1A1 
and alter the exposure of its substrates.15,39-41
One of the evolving areas in pharmacokinetics is the role 
of drug transporters in DDIs. The P-glycoprotein (P-gp) 
efflux transporter is widely distributed in the body and is 
directly responsible for the transport and elimination of many 
ART and antineoplastics, with some of the drugs also having 
the potential to modulate P-gp activity via induction or inhi-
bition. In addition to inhibiting the CYP system, ritonavir and 
cobicistat also inhibit P-gp, which can lead to increased 
exposure of antineoplastics that depend on the P-gp for their 
metabolism, absorption, and/or transport.15,39,41,42
Hepatic, renal, and biliary clearance of drugs may also 
be affected by other drug transporters, such as the multidrug 
resistance–associated proteins, the breast cancer resistance 
protein, the organic anion-transporting polypeptides, and 
the organic anion and cation transporters. Evolving data 
with ARTs and antineoplastics suggest that many of these 
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drugs can be substrates, inducers, and/or inhibitors of these 
transporters.15,42-45
In addition to pharmacokinetic (PK) DDIs, additive tox-
icities and other pharmacodynamic interactions should also 
be considered. Caution should be used, and renal function 
should be closely monitored if TDF is coadministered with 
chemotherapy that is nephrotoxic or that competes for renal 
tubular secretion (eg, ifosfamide, platinum compounds).40,41 
The newer TAF prodrug results in higher levels of intracel-
lular tenofovir in HIV-infected CD4 lymphocytes and 90% 
lower systemic exposure of tenofovir, thereby decreasing 
the risk of nephrotoxicity.15 Cardiotoxicity and QT-interval 
prolongation is another overlapping toxicity of concern 
with some ART (rilpivirine, atazanavir) and multiple anti-
neoplastic drugs such as anthracyclines, luteinizing-hor-
mone-releasing hormone agonists/antagonists, some 
tyrosine kinase inhibitors, and others. Such combinations 
should be avoided or very closely monitored to avoid the 
risks of ventricular arrhythmias and sudden death.15,40,41
Given the toxicity profiles of antineoplastics and their 
potential narrow therapeutic indices, clinical PK studies are 
not ethical to conduct in many cases, and data with most 
combinations are lacking. The potential DDIs of the most 
commonly used ART with selected injectable and oral 
antineoplastics are described in Tables 3 and 4.15,16,37,46-60 
These tables should be used as a guide, and whenever pos-
sible, oncology and HIV clinicians, along with pharmacists 
specializing in these fields, should review the proposed 
combination therapies for possible DDIs and overlapping 
toxicities.10 The possibility of enhanced toxicity or 
decreased efficacy as a result of the DDI should be evalu-
ated.10 In general, ART combinations that include a boosted 
PI, elvitegravir with cobicistat boosting, or efavirenz have 
the highest risk for DDIs with antineoplastics, whereas a 
regimen that contains INSTIs bictegravir, dolutegravir, or 
raltegravir along with a NRTI such as emtricitabine, TAF, or 
abacavir have a minimal DDI potential.
Laboratory Monitoring and Drug Toxicities
Baseline labs that should be performed at entry into HIV 
care to permit selection of initial treatment and assessment 
of response/toxicities include HIV RNA, HIV resistance 
testing, CD4 count, hepatitis B virus serologies, hepatitis C 
virus screening, basic metabolic panel, liver function tests, 
complete blood count with differential, fasting lipid profile, 
fasting glucose or hemoglobin A
1C
 (A1C), urinalysis, and 
pregnancy test (prior to ART initiation in women of 
Table 1. Metabolism Profile of Antiretroviral Agents.13-15
CYP Substrate CYP Inhibitor CYP Inducer P-glycoprotein UGT1A1 Other Transporters
NRTIs
 Lamivudine — — — — — OCT substrate
 Emtricitabine — — — — — MATE substrate
 Abacavir — — — Substrate — BCRP substrate
 Tenofovir DF — — — Substrate — OAT substrate
 Tenofovir AF — — — — — BCRP, OAT substrate
NNRTIs
 Doravirine 3A4/5a — — — — —
 Efavirenz 3A4,a 2B6a — 3A4, 2B6, 2C19 — — BCRP substrate
 Rilpivirine 3A4 — — — — —
PIs
 Atazanavir 3A4a 3A4a — — Inhibitor BCRP, OAT inhibitor
 Darunavir 3A4a 3A4,a 2D6 — Substrate, inducer — —
INSTIs
 Bictegravir 3A4 — — — Substrate OCT, MATE inhibitor
 Dolutegravir 3A4 — — Substrate Substrate OCT, MATE inhibitor
 Elvitegravir 3A4a — — — Substrate —
 Raltegravir — — — Substrate Substrate BCRP substrate
PK boosters
 Cobicistat 3A4a 3A4,a 2D6 — Inhibitor — BCRP, OATP inhibitor
 Ritonavir 3A4,a 1A2, 
2B6, 2D6
3A4a 2B6, 2C19, 2C9, 
2B6
Substrate, inhibitor — BCRP, MRP, OATP 
inhibitor
Abbreviations: AF, alafenamide fumarate; BCRP, breast cancer resistance protein; CYP, cytochrome; DF, disoproxil fumarate; INSTI, integrase strand 
transfer inhibitor; MATE, multidrug and toxin extrusion protein; MRP, multidrug resistance–associated protein; NNRTI, nonnucleoside reverse 
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OAT, organic anionic transporter; OATP, organic anion-transporting 
polypeptide; OCT, organic cation transporter; PI, protease inhibitor; PK, pharmacokinetic; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.
aMajor/strong.
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Table 2. Metabolism Profile of Common Chemotherapy Agents.13-15
CYP Substrate CYP Inhibitor CYP Inducer P-glycoprotein UGT1A1 Other Transporters
ALK inhibitors
 Alectinib 3A4 — — Inhibitor — BCRP inhibitor
 Brigatinib 3A4,a 2C8 — — Substrate — BCRP substrate
 Ceritinib 3A4a 3A4, 2C9 — Substrate — —
 Crizotinib 3A4a 3A4 — Substrate — OCT inhibitor
Alkylating agents
 Bendamustine 1A2 — — Substrate — BCRP substrate
 Chlorambucil — — — — — —
 Cyclophosphamide 3A4, 2B6,a 2C19 — — — — —
 Ifosfamide 3A4, 2B6a 3A4 3A4 — — —
Androgen metabolism inhibitors
 Abiraterone 3A4a 1A2, 2C8, 
2D6
— — — OAT inhibitor
Anthracyclines
 Doxorubicin — — — Substrate —  
 Epirubicin — — — — —  
Anti-HER2 monoclonal antibodies
 Trastuzumab — — — — — —
 Pertuzumab — — — — — —
Antiandrogen, first generation
 Bicalutamide — 3A4 — — — —
 Flutamide 3A4, 1A2a — — — — —
 Nilutamide 2C19a — — — — —
Antiandrogen, second generation
 Apalutamide 3A4, 2C8 — 3A4,a 2C19,a 2C9 Inducer — BCRP, OAT inducer
 Enzalutamide 3A4,a 2C8a — 3A4,a 2C19, 2C9 — — BCRP inhibitor
Antiestrogens
 Tamoxifen 3A4, 2C9,a 2D6a 2C9 3A4 — — —
 Toremifene 3A4,a 1A2 2C9 — — — —
Antimetabolites
 5-Fluorouracil — 2C9 — — — —
 Capecitabine — 2C9 — — — —
 Cytarabine — — — — — —
 Gemcitabine — — — — — —
 Methotrexate — — — Substrate — BCRP, OAT substrate
 Pemetrexed — — — — — OAT substrate
 Pralatrexate — — — — — BCRP, OAT substrate
Aromatase inhibitors
 Anastrozole 3A4a — — — — —
 Exemestane 3A4a — — — — —
 Letrozole 3A4, 2A6 2C19, 2A6 — — — —
BRAF/MEK inhibitors
 Dabrafenib 3A4,a 2C8a — 3A4, 2C9 Substrate — BCRP substrate, inhibitor; 
OAT inhibitor
 Trametinib — 2C8 3A4 — — —
CDK inhibitors
 Abemaciclib 3A4a — — Substrate — BCRP substrate; BCRP, 
OCT, MATE inhibitor
 Palbociclib 3A4a 3A4 — — — —
 Ribociclib 3A4a 3A4 — —
EGFR inhibitors
 Cetuximab — — — — — —
 Panitumumab — — — — — —
(continued)
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CYP Substrate CYP Inhibitor CYP Inducer P-glycoprotein UGT1A1 Other Transporters
Histone deacetylase inhibitors
 Romidepsin 3A4a — — Substrate — OAT inhibitor
 Belinostat 3A4,a 2C9, 2A6 2C8, 2C9 — Substrate Substrate —
Immunomodulators
 Lenalidomide — — — Substrate — —
 Pomalidomide 3A4, 1A2a — — Substrate — —
 Thalidomide — — — — — —
Immunotherapy
 Atezolizumab, durvalumab, 
ipilimumab, nivolumab, 
pembrolizumab
— — — — — —
LHRH agonists
 Goserelin, histrelin, 
leuprolide, triptorelin
— — — — — —
LHRH antagonists
 Degarelix — — — — — —
Monoclonal antibodies
 Brentuximab, obinutuzumab, 
rituximab
— — — — — —
mTOR inhibitors
 Everolimus 3A4a — — Substrate — —
 Temsirolimus 3A4a — — Substrate — —
PARP inhibitors
 Olaparib 3A4a — — Substrate — —
PI3K inhibitors
 Copanlisib 3A4a — — Substrate — BCRP substrate
 Idelalisib 3A4a — — Substrate — —
Platinum compounds
 Carboplatin — — — — —  
 Cisplatin — — — — — OCT, MATE substrate




3A4 — — — — —
Taxanes
 Cabazitaxel 3A4,a 2C8 — — — — —
 Docetaxel 3A4a — — Substrate — OAT substrate
 Paclitaxel 3A4,a 2C8a — — Substrate — OCT, OAT substrate
Topoisomerase inhibitors
 Etoposide 3A4,a 1A2, 2E1 — — Substrate Substrate —
 Irinotecan 3A4a — — Substrate Substrate BCRP, OCT, OAT 
substrate
Tyrosine kinase inhibitors
 Acalabrutinib 3A4a — — Substrate — BCRP substrate
 Afatinib — — — Substrate — BCRP substrate, 
inhibitor
 Axitinib 3A4/5,a 2C19, 
1A2
1A2, 2C8 — Inhibitor Substrate —
 Cabozanitinib 3A4,a 2C9 2C8 1A1 Inhibitor — MRP2 substrate
 Erlotinib 3A4,a 1A2 — — — Inhibitor —
 Gefitinib 3A4,a 2D6a — — Substrate — BCRP substrate, 
inhibitor
 Ibrutinib 3A4,a 2D6 — — Inhibitor — BCRP inhibitor
(continued)
Table 2. (continued)
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CYP Substrate CYP Inhibitor CYP Inducer P-glycoprotein UGT1A1 Other Transporters
 Imatinib 3A4,a 2D6, 2C9 3A4, 2D6 — — — BCRP inhibitor
 Lapatinib 3A4/5,a 2C8, 
2C19
3A4, 2C8 — Substrate, 
inhibitor
— BCRP, OATP inhibitor
 Lenvatinib 3A4 3A4, 2C8, 
2D6
3A4 Substrate Inhibitor BCRP substrate, OAT, 
OATP inhibitor
 Osimertinib 3A4a — 3A4, 1A2 Substrate — BCRP substrate, 
inhibitor
 Pazopanib 3A4,a 2C8, 1A2 3A4, 2C8, 
2D6
— Substrate Inhibitor BCRP substrate, OATP 
inhibitor
 Regorafenib 3A4a 3A4, 2C8, 
2D6
— — Inhibitor BCRP inhibitor
 Sorafenib 3A4 3A4, 2C8, 
2D6
— Inhibitor Inhibitor BCRP inhibitor
 Sunitinib 3A4a — — — — —
VEGF inhibitors
 Bevacizumab, ziv-aflibercept — — — — — —
Vinca alkaloids
 Vinblastine 3A4,a 2D6 — 3A4 Substrate — OAT substrate
 Vincristine 3A4a — — Substrate — OAT, OCT substrate
 Vinorelbine 3A4,a 2D6 — — — — —
Miscellaneous
 Denileukin diftitox — — — — — —
 Eribulin 3A4 — — — — —
 Fulvestrant 3A4 — — — — —
 l-Asparaginase — — — — — —
 Leucovorin — — — — — —
 Mitomycin — — — Substrate — —
 Mogamulizumab-kpkc — — — — — —
Abbreviations: ALK, anaplastic lymphoma kinase; BCRP, breast cancer resistance protein; BRAF/MEK, B-Raf/mitogen-activated protein kinase kinase; 
CDK, cyclin-dependent kinase; CYP, cytochrome; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; 
LHRH, luteinizing-hormone-releasing hormone; MATE, multidrug and toxin extrusion protein; MRP, multidrug resistance–associated protein; mTOR, 
mammalian target of rapamycin; OAT, organic anionic transporter; OATP, organic anion-transporting polypeptide; OCT, organic cation transporter; 




childbearing potential.10 If ART is started soon after entry 
into care, repeating baseline laboratory studies is not 
needed.10 Once ART is initiated (or changed), within 2 to 8 
weeks, basic metabolic panel and liver function tests should 
be assessed. These should be repeated every 3 to 6 months 
as well. Fasting glucose (or A1C) and lipid profile should be 
performed annually if a normal baseline is established.10
CD4 count should be assessed prior to and 3 months after 
initiating ART.10 During the first 2 years of ART, CD4 counts 
should be monitored every 3 to 6 months and then extended 
to every 6 months in patients who have demonstrated viro-
logical suppression for at least 2 years.10 Observed decreases 
in CD4 counts may represent adverse effects of antineoplas-
tics or the cancer itself and not necessarily poor virological 
control.10 However, continued CD4 count monitoring is 
important for predicting risk for OIs.
In an ART-naïve patient, HIV RNA should be assessed 
prior to start of treatment and then within 2 to 4 weeks of 
starting ART, continuing to monitor every 4 to 8 weeks 
until the viral load is suppressed.10 During the first 2 years 
of ART, HIV RNA should be assessed every 3 to 4 months, 
and if a patient achieves virological suppression for at 
least 2 years, HIV RNA assessment can be extended to 
once every 6 months. Following the start of induction che-
motherapy, HIV RNA should be assessed once monthly in 
the first 3 months and then every 3 months to assess any 
effect the antineoplastics may have on potential reduction 
in ART concentrations because of DDIs.10,37 Since HIV 
RNA monitoring is a more precise reflection of virological 
efficacy of an ART regimen than CD4 count, it is a crucial 
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In addition to the above laboratory monitoring, a patient’s 
ART regimen should be reviewed to determine if any addi-
tional monitoring is needed. For example, serum phospho-
rous should be checked at baseline and every 3 to 6 months 
in patients with chronic kidney disease who are taking regi-
mens that contain TAF or TDF. Urine glucose and protein 
testing should be performed before and every 6 months dur-
ing treatment with TAF and TDF.15 Reference information 
for drug toxicities and special considerations are available 
for each drug class of ART.15 Monitoring patients’ medica-
tion regimens for DDIs is crucial for minimizing toxicities 
and maintaining virological suppression.
Opportunistic Infections
OIs occur more frequently in PLWH as a result of the 
immunosuppression that can occur in the course of HIV dis-
ease. However, because of the improved virological control 
that has resulted from durable, suppressive ART, OI-related 
morbidity and mortality have been reduced substantially.15 
This reemphasizes the need for timely initiation and moni-
toring of ART to achieve virological suppression in an effort 
to also reduce the incidence of OIs.
When considering antimicrobial prophylaxis for PLWH 
and cancer, an individual’s OI risk can be assessed via CD4 
count thresholds and serological testing and history of 
exposure to OIs.61 The use of ART, achievement of virologi-
cal suppression, and duration of its use are considered. 
Additionally, overall infection risk in patients with cancer 
can be graded as low, intermediate, or high, factoring in 
malignancies that cause immunosuppression, duration of 
neutropenia, history of exposure to antineoplastics, and the 
intensity of immunosuppressive therapies used.62 It is also 
helpful to consider DDIs between agents used for OI pro-
phylaxis and ART and antineoplastics. Thus, a multidisci-
plinary approach involving the oncologist, infectious 
diseases, and clinical pharmacists is beneficial in balancing 
all these considerations. In a given patient, OI prophylaxis 
can be prescribed based on CD4 count and HIV status. 
Once cancer chemotherapy is prescribed, additional agents 
for OI prevention are added accordingly.37 Agents used for 
OI prophylaxis may require adjustment if CD4 counts 
decline during chemotherapy, if they increase following 
completion of treatment, or if they augment toxicities of 
antineoplastics, such as myelosuppression. These recom-
mendations also advise collaboration among providers to 
permit modifications and adjustments.37
Management of Malignancy in PLWH
As previously described, the pharmacist caring for PLWH 
and malignancies must critically review potential interac-
tions resulting from the overlapping of medications. A 
desired plan will minimize or avoid PK interactions and 
optimize timing of medications for both conditions. In addi-
tion to the therapies for malignancy, drug interactions 
should be screened between ART and medications used for 
supportive care. Antiemetics, opioids, and antibiotics are 
commonly used for symptom prevention and management. 
One area of concern is the potential for cardiotoxicity with 
QT-interval prolongation from the combination of some 
oral antineoplastics, serotonin antagonist antiemetics, and 
PIs. Additional aspects related to management of malignan-
cies include radiation and surgery.
Radiotherapy in combination with other modalities is 
part of treating many cancers. It can be used in curative and 
palliative settings. Studies of the efficacy and tolerability of 
various radiotherapy approaches with or without antineo-
plastics in PLWH were evaluated in a review of 44 studies, 
with most in anal cancer. The authors concluded that for the 
majority of patients, clinical outcomes were similar to those 
in patients without HIV.63 Another review of data from 21 
studies, primarily in anal cancer, demonstrated similar tol-
erability of radiation therapy between PLWH and unin-
fected individuals.64 However, data are more limited in 
other cancers and in combination with immunothera-
pies.10,65 A 52-year-old man with NSCLC experienced peri-
cardial effusion and interstitial pneumonia after 5 weeks of 
stereotactic body radiotherapy and 3 cycles of pembroli-
zumab. After the interruption of pembrolizumab, tumor 
growth progressed. It is not clear whether the stereotactic 
body radiotherapy and pembrolizumab interaction was the 
cause of these events.65
Surgery is a primary part of treatment for solid tumor 
malignancies such as lung, anal, prostate, liver, and breast 
cancers. In the modern ART era, some experts believe that 
the overall health or performance status is a more reliable 
indicator of successful surgical outcomes than CD4 count 
or viral load in PLWH, and that HIV status should not affect 
choices about surgery.10 However these recommendations 
are based on studies with small sample sizes, which are not 
necessarily representative of all types of surgeries involved 
in removal of malignancies. The 30-day postoperative mor-
tality was compared in a retrospective analysis of PLWH 
and uninfected individuals undergoing a variety of proce-
dures. The population of PLWH included 202 individuals 
with cancer. In this cohort, overall mortality rates were low, 
but mortality in PLWH was increased compared with unin-
fected individuals at all CD4 levels. Age and hypoalbumin-
emia also affected surgical outcomes.66
Conclusion
The availability of more effective ART has transformed AIDS 
into a chronic medical condition. PLWH are receiving more 
effective care and living longer lives. They are experiencing 
age-related comorbidities consistent with the general popula-
tion, which include malignancies. Additional information 
830 Annals of Pharmacotherapy 53(8)
regarding management of DDIs in PLWH and malignancy is 
a need. Pharmacists play an important role in the multidisci-
plinary management of this patient population by helping 
assess DDIs and minimizing drug-related problems.
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